Lantern Pharma (LTRN) Projected to Release Quarterly Earnings on Wednesday

Lantern Pharma (NASDAQ:LTRN) is expected to post its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Lantern Pharma to announce earnings of ($0.38) per share for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Lantern Pharma (NASDAQ:LTRN) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06.

Lantern Pharma Stock Performance

NASDAQ:LTRN opened at $2.75 on Wednesday. The company has a fifty day moving average of $3.45 and a two-hundred day moving average of $2.89. The stock has a market capitalization of $35.09 million, a PE ratio of -1.90 and a beta of 2.34. Lantern Pharma has a fifty-two week low of $1.11 and a fifty-two week high of $5.74.

Insiders Place Their Bets

In other news, Director Lee Troy Schalop acquired 48,544 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were bought at an average price of $2.06 per share, for a total transaction of $100,000.64. Following the acquisition, the director owned 48,544 shares of the company’s stock, valued at approximately $100,000.64. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director D Jeffrey Keyser bought 48,544 shares of the stock in a transaction on Tuesday, May 12th. The shares were acquired at an average cost of $2.06 per share, for a total transaction of $100,000.64. Following the purchase, the director owned 94,303 shares in the company, valued at $194,264.18. The trade was a 106.09% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Lantern Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cetera Investment Advisers purchased a new stake in Lantern Pharma during the 4th quarter valued at about $37,000. XTX Topco Ltd purchased a new position in Lantern Pharma in the 2nd quarter worth approximately $40,000. CIBC Private Wealth Group LLC purchased a new position in Lantern Pharma in the 4th quarter worth approximately $47,000. Two Sigma Investments LP acquired a new position in shares of Lantern Pharma during the 3rd quarter worth approximately $70,000. Finally, Susquehanna International Group LLP acquired a new position in shares of Lantern Pharma during the 3rd quarter worth approximately $170,000. 28.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LTRN has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Lantern Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings upgraded shares of Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Lantern Pharma Company Profile

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.